cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.8b32wg
title: Occurrence Download

description: A dataset containing 73 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Platanthera urceolata"
 ]
}

 The dataset includes 73 records from 18 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006417-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31227916
title: Supplementary Material for: Case Series of Eosinophilic Pustular Folliculitis with Exclusive Scalp and Facial Involvement: A Distinct Entity?

description: Abstract
Eosinophilic pustular folliculitis (EPF) is a rare, non-infectious dermatosis characterized by pruritic, recurrent episodes of follicular papulopustules. Three forms of eosinophilic pustular folliculitis have been described: classic EPF (Ofuji disease), immunosuppression- or HIV-associated EPF, and infantile EPF. Histopathologically, eosinophils are frequently observed within and around the follicular epithelium. In our four non-infant patients with negative anti-HIV antibody results, involvement was limited exclusively to the scalp and face. Based on these findings, we suggest that this presentation may represent a distinct clinical subtype of eosinophilic pustular folliculitis characterized by isolated scalp and facial involvement, and we present this case series to highlight this entity.
DOI: 10.6084/m9.figshare.31227916.v1
title: Supplementary Material for: Case Series of Eosinophilic Pustular Folliculitis with Exclusive Scalp and Facial Involvement: A Distinct Entity?

description: Abstract
Eosinophilic pustular folliculitis (EPF) is a rare, non-infectious dermatosis characterized by pruritic, recurrent episodes of follicular papulopustules. Three forms of eosinophilic pustular folliculitis have been described: classic EPF (Ofuji disease), immunosuppression- or HIV-associated EPF, and infantile EPF. Histopathologically, eosinophils are frequently observed within and around the follicular epithelium. In our four non-infant patients with negative anti-HIV antibody results, involvement was limited exclusively to the scalp and face. Based on these findings, we suggest that this presentation may represent a distinct clinical subtype of eosinophilic pustular folliculitis characterized by isolated scalp and facial involvement, and we present this case series to highlight this entity.
DOI: 10.6084/m9.figshare.31227919
title: Supplementary Material for: Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

description: Background
Critically ill patients exhibit acute physiological changes leading to marked antibiotic exposure variability and an increased probability of either subtherapeutic or potentially toxic exposures. Beta-lactam antibiotics are often affected by these physiological changes, leading to variable and often subtherapeutic exposures. Furthermore, although this medication class is associated with minimal concentration-related adverse effects, recent evidence suggests that beta-lactams may be associated with neurotoxicity and nephrotoxicity. Therefore, methods to increase the probability of a therapeutic exposure may be beneficial for critically ill patients. Model Informed Precision Dosing (MIPD) is an emerging strategy using advanced computer models to individualise dosing in this vulnerable population with or without therapeutic drug monitoring (TDM). By tailoring therapy to the individual patient scenario, MIPD aims to improve clinical outcomes by enhancing the likelihood of effective and safe therapy. 

Summary
MIPD-guided beta-lactam antibiotic dosing may improve the probability of attaining target therapeutic exposures and clinical cure rates compared to standard fixed dosing in critically ill patients. Moreover, MIPD allows clinicians to target higher beta-lactam antibiotic exposures whilst minimising the risk of toxicity, when the goal of treatment is both improving clinical cure rates and suppressing the probability of antibiotic resistance emergence. No differences in mortality and adverse event reduction compared to standard dosing has been currently identified in the literature. However, the exact potential of MIPD has yet to be determined given the significant limitations in the current evidence base, including heterogeneous study designs, small sample sizes, inconsistent implementation strategies and variable outcome definitions. Clinical practice and future research should optimise MIPD performance by selecting appropriate and innovative beta-lactam antibiotic exposure models, as well as identify methods to instigate early MIPD dosing and timely TDM dose adjustments. This may further improve clinical and economic outcomes for critically ill patients.
DOI: 10.6084/m9.figshare.31227919.v1
title: Supplementary Material for: Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

description: Background
Critically ill patients exhibit acute physiological changes leading to marked antibiotic exposure variability and an increased probability of either subtherapeutic or potentially toxic exposures. Beta-lactam antibiotics are often affected by these physiological changes, leading to variable and often subtherapeutic exposures. Furthermore, although this medication class is associated with minimal concentration-related adverse effects, recent evidence suggests that beta-lactams may be associated with neurotoxicity and nephrotoxicity. Therefore, methods to increase the probability of a therapeutic exposure may be beneficial for critically ill patients. Model Informed Precision Dosing (MIPD) is an emerging strategy using advanced computer models to individualise dosing in this vulnerable population with or without therapeutic drug monitoring (TDM). By tailoring therapy to the individual patient scenario, MIPD aims to improve clinical outcomes by enhancing the likelihood of effective and safe therapy. 

Summary
MIPD-guided beta-lactam antibiotic dosing may improve the probability of attaining target therapeutic exposures and clinical cure rates compared to standard fixed dosing in critically ill patients. Moreover, MIPD allows clinicians to target higher beta-lactam antibiotic exposures whilst minimising the risk of toxicity, when the goal of treatment is both improving clinical cure rates and suppressing the probability of antibiotic resistance emergence. No differences in mortality and adverse event reduction compared to standard dosing has been currently identified in the literature. However, the exact potential of MIPD has yet to be determined given the significant limitations in the current evidence base, including heterogeneous study designs, small sample sizes, inconsistent implementation strategies and variable outcome definitions. Clinical practice and future research should optimise MIPD performance by selecting appropriate and innovative beta-lactam antibiotic exposure models, as well as identify methods to instigate early MIPD dosing and timely TDM dose adjustments. This may further improve clinical and economic outcomes for critically ill patients.
DOI: 10.6084/m9.figshare.31227922
title: Supplementary Material for: Sister Mary Joseph’s Nodule Presenting with an Ulcerated Umbilicus as an External Diagnostic Clue Revealing a Deeply Situated Pancreatic Tail Cancer

description: Case Presentation: An 84-year-old female patient presented with umbilical hemorrhage. A central depressed lesion with reddish and multinodular change was exhibited in the umbilicus, showing with an ulcerated, infiltrative appearance. The patient was strongly suspected of having Sister Mary Joseph’s nodule (SMJN). Referring to the tertiary care hospital, laboratory tests revealed an elevated CA19-9 level of 15,366 U/mL, and a computed tomography scan showed a pancreatic tail tumor and the umbilical mass. Biopsy of the umbilical lesion revealed adenocarcinoma cells infiltrated in the skin, with immunohistochemical staining positive for CK7 and CA19-9 but negative for CK20. Therefore, the umbilical lesion was consequently diagnosed as metastasis from pancreatic tail cancer, representing SMJN. The patient died two months after the initial presentation. Conclusions: Ulcerated umbilical lesions should warrant clinical consideration of Sister Mary Joseph’s nodule, as they can serve as a critical diagnostic clue to a deeply situated pancreatic tail cancer.
DOI: 10.15468/dl.qs683z
title: Occurrence Download

description: A dataset containing 62 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Zieria alata",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 62 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006418-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31227922.v1
title: Supplementary Material for: Sister Mary Joseph’s Nodule Presenting with an Ulcerated Umbilicus as an External Diagnostic Clue Revealing a Deeply Situated Pancreatic Tail Cancer

description: Case Presentation: An 84-year-old female patient presented with umbilical hemorrhage. A central depressed lesion with reddish and multinodular change was exhibited in the umbilicus, showing with an ulcerated, infiltrative appearance. The patient was strongly suspected of having Sister Mary Joseph’s nodule (SMJN). Referring to the tertiary care hospital, laboratory tests revealed an elevated CA19-9 level of 15,366 U/mL, and a computed tomography scan showed a pancreatic tail tumor and the umbilical mass. Biopsy of the umbilical lesion revealed adenocarcinoma cells infiltrated in the skin, with immunohistochemical staining positive for CK7 and CA19-9 but negative for CK20. Therefore, the umbilical lesion was consequently diagnosed as metastasis from pancreatic tail cancer, representing SMJN. The patient died two months after the initial presentation. Conclusions: Ulcerated umbilical lesions should warrant clinical consideration of Sister Mary Joseph’s nodule, as they can serve as a critical diagnostic clue to a deeply situated pancreatic tail cancer.
DOI: 10.6084/m9.figshare.31227925
title: Supplementary Material for: Dermatofibrosarcoma Protuberans at the Presumed Injection Site Following CoronaVac COVID-19 Vaccination: A Case Report

description: Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, locally aggressive cutaneous sarcoma. Trauma and scars have been proposed as potential triggers in a subset of cases. Case presentation: We report a 30-year-old man who developed a progressively enlarging mass in the left deltoid region within several months after receiving two doses of the CoronaVac COVID-19 vaccine administered to the same arm. The lesion was diagnosed as DFSP approximately 19 months after vaccination. Histopathology showed a storiform spindle-cell neoplasm with diffuse CD34 positivity, and fluorescence in situ hybridization demonstrated the COL1A1–PDGFB fusion, consistent with DFSP. The tumor was managed with wide local excision with 2-cm clinical margins; final margins were negative. At 24 months of follow-up after surgery, there was no evidence of local recurrence or metastasis. Conclusions: This case illustrates a temporal association between a new mass at a presumed injection site and DFSP. While causality cannot be inferred from a single case, persistent post-injection nodules should prompt evaluation. The overall benefits of COVID-19 vaccination remain substantial.
DOI: 10.6084/m9.figshare.31227925.v1
title: Supplementary Material for: Dermatofibrosarcoma Protuberans at the Presumed Injection Site Following CoronaVac COVID-19 Vaccination: A Case Report

description: Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, locally aggressive cutaneous sarcoma. Trauma and scars have been proposed as potential triggers in a subset of cases. Case presentation: We report a 30-year-old man who developed a progressively enlarging mass in the left deltoid region within several months after receiving two doses of the CoronaVac COVID-19 vaccine administered to the same arm. The lesion was diagnosed as DFSP approximately 19 months after vaccination. Histopathology showed a storiform spindle-cell neoplasm with diffuse CD34 positivity, and fluorescence in situ hybridization demonstrated the COL1A1–PDGFB fusion, consistent with DFSP. The tumor was managed with wide local excision with 2-cm clinical margins; final margins were negative. At 24 months of follow-up after surgery, there was no evidence of local recurrence or metastasis. Conclusions: This case illustrates a temporal association between a new mass at a presumed injection site and DFSP. While causality cannot be inferred from a single case, persistent post-injection nodules should prompt evaluation. The overall benefits of COVID-19 vaccination remain substantial.
DOI: 10.6084/m9.figshare.31227928
title: Supplementary Material for: Aging-related morphological remodeling in cerebral arteries: A quantitative magnetic resonance angiography study

description: Introduction: Age-related arterial remodeling is a key contributor to cardiovascular disease, but morphological changes in cerebral arteries with aging remain poorly characterized. We aimed to investigate age-related alterations in cerebral arterial morphology using quantitative analysis.
Methods: This retrospective observational study analyzed brain magnetic resonance angiography images from 1,168 healthy individuals without cerebrovascular disease. An automated arterial measurement system was used to quantify morphological features, categorized into size metrics (e.g., area), shape metrics (e.g., minimum [min]-maximum [max] diameter ratio), and tortuosity metrics (e.g., curvature). Correlation analyses were performed between age and arterial features, and multivariable regression analyses were conducted to evaluate age-related effects across the entire cerebrovascular tree and individual cerebral arterial segments.
Results: Luminal area increased steadily with age (rho = 0.217, p &lt; 0.001). The min-max diameter ratio remained stable until the fifties and then increased rapidly after the fifth decade (rho = 0.144, p &lt; 0.001), reflecting more circular vessel configurations. Curvature did not change significantly with age. Age was independently associated with the global features of cerebral arteries, including mean area (β = 0.285; 95% CI, 0.222–0.347) and mean min-max diameter ratio (β = 0.215; 95% CI, 0.147–0.282), but showed no significant association. At the level of individual artery analysis, the effect of age on luminal area was more pronounced in larger arteries, whereas age-related changes in the min–max diameter ratio were more evident in medium-sized arteries. Interaction analysis between age and vascular risk factors revealed a significant effect of interaction on arterial shape.
Conclusions: Cerebral arteries show distinct age-related morphological alterations, characterized by luminal enlargement and greater circularity. These changes vary with arterial size and location, suggesting differential susceptibility of cerebral arteries to the effects of aging.
DOI: 10.6084/m9.figshare.31227928.v1
title: Supplementary Material for: Aging-related morphological remodeling in cerebral arteries: A quantitative magnetic resonance angiography study

description: Introduction: Age-related arterial remodeling is a key contributor to cardiovascular disease, but morphological changes in cerebral arteries with aging remain poorly characterized. We aimed to investigate age-related alterations in cerebral arterial morphology using quantitative analysis.
Methods: This retrospective observational study analyzed brain magnetic resonance angiography images from 1,168 healthy individuals without cerebrovascular disease. An automated arterial measurement system was used to quantify morphological features, categorized into size metrics (e.g., area), shape metrics (e.g., minimum [min]-maximum [max] diameter ratio), and tortuosity metrics (e.g., curvature). Correlation analyses were performed between age and arterial features, and multivariable regression analyses were conducted to evaluate age-related effects across the entire cerebrovascular tree and individual cerebral arterial segments.
Results: Luminal area increased steadily with age (rho = 0.217, p &lt; 0.001). The min-max diameter ratio remained stable until the fifties and then increased rapidly after the fifth decade (rho = 0.144, p &lt; 0.001), reflecting more circular vessel configurations. Curvature did not change significantly with age. Age was independently associated with the global features of cerebral arteries, including mean area (β = 0.285; 95% CI, 0.222–0.347) and mean min-max diameter ratio (β = 0.215; 95% CI, 0.147–0.282), but showed no significant association. At the level of individual artery analysis, the effect of age on luminal area was more pronounced in larger arteries, whereas age-related changes in the min–max diameter ratio were more evident in medium-sized arteries. Interaction analysis between age and vascular risk factors revealed a significant effect of interaction on arterial shape.
Conclusions: Cerebral arteries show distinct age-related morphological alterations, characterized by luminal enlargement and greater circularity. These changes vary with arterial size and location, suggesting differential susceptibility of cerebral arteries to the effects of aging.
DOI: 10.6084/m9.figshare.31227931
title: Supplementary Material for: Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk：A Meta- Analysis Systemic Review

description: Objectives: To evaluate the effects of Nafamostat versus heparin on anticoagulation efficacy, filter lifespan, bleeding and other adverse events in patients with high bleeding risk undergoing continuous renal replacement therapy.
Methods: Computerized retrieval was conducted in PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wanfang, and VIP databases for relevant English or Chinese studies published since their establishment until June 22, 2025. Thirteen studies comparing Nafamostat with heparin for patients with high bleeding risk during continuous renal replacement therapy were included. Two researchers independently performed literature screening, data extraction, and evaluation of literature quality. Meta-analysis was conducted using Stata 18 software.
Results: A total of 11 observational studies were included in this research, involving 1,354 patients. The meta-analysis results showed that Nafamostat significantly reduced the risk of bleeding compared to heparin [RR = 0.38, 95% CI (0.20, 0.74), P &lt; 0.05], but there were no statistically significant differences in filter lifespan [SMD = -0.01, 95% CI (-0.50, 0.48), P = 0.053], coagulation events [RR = 0.92, 95% CI (0.33, 2.54), P = 0.868], and mortality [RR = 1.20, 95% CI (0.87, 1.66), P = 0.256]. The subgroup analysis comparing the Nafamostat group to the heparin group showed that NM significantly reduced the risk of bleeding compared to LMWH [RR = 0.20, 95% CI (0.06, 0.71), P = 0.013], while the bleeding risk in the unfractionated heparin group [RR = 0.46, 95% CI (0.20, 0.74), P = 0.071] showed a downward trend but did not reach statistical significance. Patients with platelet counts &lt; 100×10⁹/L [RR = 0.25, 95% CI (0.07, 0.88), P = 0.031] had significantly lower bleeding risk compared to those with platelet counts ≥ 100×10⁹/L [RR = 0.48, 95% CI (0.19, 1.22), P = 0.121].
Conclusion: This systematic review and meta-analysis indicate that in patients with a high risk of bleeding who receive continuous renal replacement therapy (CRRT), Nafamostat has similar anticoagulant efficacy to heparin and can effectively maintain the patency of the extracorporeal circulation tubing. Moreover, Nafamostat significantly reduces the risk of bleeding. Therefore, for CRRT patients with a high risk of bleeding, it is recommended to prioritize the use of Nafamostat as the first-line anticoagulation regimen.
DOI: 10.6084/m9.figshare.31227931.v1
title: Supplementary Material for: Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk：A Meta- Analysis Systemic Review

description: Objectives: To evaluate the effects of Nafamostat versus heparin on anticoagulation efficacy, filter lifespan, bleeding and other adverse events in patients with high bleeding risk undergoing continuous renal replacement therapy.
Methods: Computerized retrieval was conducted in PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wanfang, and VIP databases for relevant English or Chinese studies published since their establishment until June 22, 2025. Thirteen studies comparing Nafamostat with heparin for patients with high bleeding risk during continuous renal replacement therapy were included. Two researchers independently performed literature screening, data extraction, and evaluation of literature quality. Meta-analysis was conducted using Stata 18 software.
Results: A total of 11 observational studies were included in this research, involving 1,354 patients. The meta-analysis results showed that Nafamostat significantly reduced the risk of bleeding compared to heparin [RR = 0.38, 95% CI (0.20, 0.74), P &lt; 0.05], but there were no statistically significant differences in filter lifespan [SMD = -0.01, 95% CI (-0.50, 0.48), P = 0.053], coagulation events [RR = 0.92, 95% CI (0.33, 2.54), P = 0.868], and mortality [RR = 1.20, 95% CI (0.87, 1.66), P = 0.256]. The subgroup analysis comparing the Nafamostat group to the heparin group showed that NM significantly reduced the risk of bleeding compared to LMWH [RR = 0.20, 95% CI (0.06, 0.71), P = 0.013], while the bleeding risk in the unfractionated heparin group [RR = 0.46, 95% CI (0.20, 0.74), P = 0.071] showed a downward trend but did not reach statistical significance. Patients with platelet counts &lt; 100×10⁹/L [RR = 0.25, 95% CI (0.07, 0.88), P = 0.031] had significantly lower bleeding risk compared to those with platelet counts ≥ 100×10⁹/L [RR = 0.48, 95% CI (0.19, 1.22), P = 0.121].
Conclusion: This systematic review and meta-analysis indicate that in patients with a high risk of bleeding who receive continuous renal replacement therapy (CRRT), Nafamostat has similar anticoagulant efficacy to heparin and can effectively maintain the patency of the extracorporeal circulation tubing. Moreover, Nafamostat significantly reduces the risk of bleeding. Therefore, for CRRT patients with a high risk of bleeding, it is recommended to prioritize the use of Nafamostat as the first-line anticoagulation regimen.